216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors
Markman B, LoRusso P, Patnaik A, Heath E, Laird A, van Leeuwen B, Papadopoulos K, Baselga J. 216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors. European Journal Of Cancer Supplements 2008, 6: 68-69. DOI: 10.1016/s1359-6349(08)72148-7.Peer-Reviewed Original Research